These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 11817593)

  • 1. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
    Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
    Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
    Charni N; Juillet F; Garnero P
    Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis.
    Marotte H; Gineyts E; Miossec P; Delmas PD
    Ann Rheum Dis; 2009 Jul; 68(7):1197-200. PubMed ID: 18713784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis.
    Garnero P; Ayral X; Rousseau JC; Christgau S; Sandell LJ; Dougados M; Delmas PD
    Arthritis Rheum; 2002 Oct; 46(10):2613-24. PubMed ID: 12384919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage.
    Garnero P; Piperno M; Gineyts E; Christgau S; Delmas PD; Vignon E
    Ann Rheum Dis; 2001 Jun; 60(6):619-26. PubMed ID: 11350852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study.
    Garnero P; Landewé R; Boers M; Verhoeven A; Van Der Linden S; Christgau S; Van Der Heijde D; Boonen A; Geusens P
    Arthritis Rheum; 2002 Nov; 46(11):2847-56. PubMed ID: 12428224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy.
    Jansen NW; Roosendaal G; Lundin B; Heijnen L; Mauser-Bunschoten E; Bijlsma JW; Theobald M; Lafeber FP
    Arthritis Rheum; 2009 Jan; 60(1):290-8. PubMed ID: 19116938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
    Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
    J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis.
    Gineyts E; Mo JA; Ko A; Henriksen DB; Curtis SP; Gertz BJ; Garnero P; Delmas PD
    Ann Rheum Dis; 2004 Jul; 63(7):857-61. PubMed ID: 15194584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.
    Young-Min S; Cawston T; Marshall N; Coady D; Christgau S; Saxne T; Robins S; Griffiths I
    Arthritis Rheum; 2007 Oct; 56(10):3236-47. PubMed ID: 17907159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
    J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression.
    Hakala M; Risteli J; Aman S; Kautiainen H; Korpela M; Hannonen P; Leirisalo-Repo M; Laasonen L; Paimela L; Möttönen T;
    Scand J Rheumatol; 2008; 37(2):90-3. PubMed ID: 18415764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
    Fraser A; Fearon U; Billinghurst RC; Ionescu M; Reece R; Barwick T; Emery P; Poole AR; Veale DJ
    Arthritis Rheum; 2003 Nov; 48(11):3085-95. PubMed ID: 14613270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs.
    Hashimoto J; Garnero P; van der Heijde D; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Yoshikawa H; Nishimoto N
    Mod Rheumatol; 2009; 19(3):273-82. PubMed ID: 19452245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum cartilage oligomeric matrix protein determines the subset of patients with early-stage rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase-3, and MRI-proven bone erosion.
    Fujikawa K; Kawakami A; Tamai M; Uetani M; Takao S; Arima K; Iwamoto N; Aramaki T; Kawashiri S; Ichinose K; Kamachi M; Nakamura H; Origuchi T; Ida H; Aoyagi K; Eguchi K
    J Rheumatol; 2009 Jun; 36(6):1126-9. PubMed ID: 19447929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis.
    Landewé R; Geusens P; Boers M; van der Heijde D; Lems W; te Koppele J; van der Linden S; Garnero P
    Arthritis Rheum; 2004 May; 50(5):1390-9. PubMed ID: 15146408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation.
    Gineyts E; Garnero P; Delmas PD
    Rheumatology (Oxford); 2001 Mar; 40(3):315-23. PubMed ID: 11285380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
    Woo JH; Lee HJ; Sung IH; Kim TH
    J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.